“An endocrinologist, a cardiologist and a nephrologist walk into a bar...”
Cross-specialty debates in diabetes
SPEAKERS
Dr
Silvio Inzucchi
Director of the Yale Medicine Diabetes Center, USA
Chairman
Dr
Sarah Jarvis
GP, Patient Platform Limited, London UK
Speaker
Professor
Francesco Giorgino
University of Bari Aldo Moro, Bari, Italy
Speaker
Professor
Nikolaus Marx
Head of the Department of Internal Medicine I, University Hospital Aachen, Germany
Speaker
Professor
Merlin Thomas
Monash University, Australia
Speaker
Agenda
-
Monday21 September
-
14:30 CEST
-
Welcome and introduction EMPA-REG OUTCOME: 5 years laterSilvio Inzucchi and Sarah Jarvis
14:35 CEST-
Metformin should remain as ‘foundation therapy’ for the majority of patients with T2D Yes (Francesco Giorgino) No (Nikolaus Marx)Francesco Giorgino and Nikolaus MarxModerator: Silvio Inzucchi
14:55 CEST-
The preferred second-line therapy in patients with T2D is: An SGLT2 inhibitor (Silvio Inzucchi) A GLP-1 RA (Francesco Giorgino)Silvio Inzucchi and Francesco GiorginoModerator: Merlin Thomas
15:15 CEST-
The most important organ in T2D is: The heart (Nikolaus Marx) The kidney (Merlin Thomas)Nikolaus Marx and Merlin ThomasModerator: Silvio Inzucchi
15:35 CEST-
The PCP perspective on patient careSarah Jarvis
15:45 CEST-
Panel discussion and Q&AF Giorgino, S Jarvis, N Marx and M ThomasModerator: Silvio Inzucchi
16:00 CEST-
Final remarks and closeSilvio Inzucchi
-
Organised by the Boehringer Ingelheim & Eli Lilly and Company Alliance
